参芪扶正注射液联合化疗治疗非小细胞肺癌临床研究  

Clinical Study on Shenqi Fuzheng Injection Combined with Chemotherapy for NonSmall Cell Lung Cancer

作　　者：王璟珂[1] 郝帅 孙亚琳 WANG Jingke;HAO Shuai;SUN Yalin

机构地区：[1]河南科技大学第一附属医院开元院区胸外科,河南洛阳471003

出　　处：《新中医》2020年第24期109-111,共3页New Chinese Medicine

摘　　要：目的:观察参芪扶正注射液联合化疗治疗非小细胞肺癌(NSCLC)的临床疗效。方法:将NSCLC患者80例随机分为2组,对照组40例给予GP化疗,联合组40例给予GP化疗+参芪扶正注射液治疗。观察比较2组治疗前后血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原199 (CA199)、经元特异性烯醇化酶(NSE)]及T淋巴细胞亚群(CD4^+、CD4^+/CD8^+)水平变化,观察比较2组近期疗效与不良反应情况。结果:总有效率联合组为60.0%,对照组为37.5%,2组比较,差异有统计学意义(P<0.05)。治疗后,2组患者血清CEA、CA199、NSE水平均较治疗前明显降低(P<0.05),且联合组各项水平均低于对照组(P<0.05)。治疗后2组CD4^+、CD4^+/CD8^+均较治疗前显著升高(P<0.05),且联合组2项指标改善较对照组更显著(P<0.05)。治疗过程中,联合组血常规异常、消化道反应、乏力及其他不良反应发生率均低于对照组,差异均有统计学意义(P<0.05)。结论:黄芪扶正注射液联合GP化疗治疗NSCLC,不仅可增加近期临床总有效率、减少不良反应,且可降低血清肿瘤标志物水平,增强免疫功能。Objective:To observe the clinical effect of Shenqi Fuzheng injection combined with chemotherapy for nonsmall cell lung cancer(NSCLC). Methods: A total of 80 cases of NSCLC patients were randomly divided into two groups,40 cases in each group. The control group was given GP chemotherapy,and the combination group was additionally treated with Shenqi Fuzheng injection based on the treatment of the control group. Before and after treatment,the changes in the levels of serum tumor markers including carcinoembryonic antigen(CEA), carbohydrate antigen(CA199) and neuron specific enolase(NSE) as well as T cell subsets including CD4^+ and CD4^+/CD8^+in the two groups were observed and compared. The recent curative effect and adverse reactions in the two groups were observed and compared. Results:The total effective rate was 60.0% in the combination group and 37.5% in the control group, the difference being significant(P<0.05). After treatment,the levels of CEA,CA199 and NSE in serum in the two groups were significantly decreased when compared with those before treatment(P<0.05), and all the levels in the combination group were lower than those in the control group(P<0.05). After treatment,CD4^+ and CD4^+/CD8^+in the two groups were significantly increased when compared with those before treatment(P<0.05),and the improvement of the two above indexes in the combination group was more significant than that in the control group(P<0.05). During treatment,the incidence of abnormal blood routine,digestive tract reaction,fatigue and other adverse reactions in the combination group was lower than that in the control group, differences being significant(P<0.05). Conclusion:The therapy of Shenqi Fuzheng injection combined with GP chemotherapy for NSCLC can not only increase the short-term clinical total effective rate and reduce the adverse reactions,but also reduce the levels of serum tumor markers and enhance the immune function.

关 键 词：非小细胞肺癌 化疗 参芪扶正注射液 免疫功能 

分 类 号：R734.2[医药卫生—肿瘤]